Literature DB >> 17923639

Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy.

Luana Benedetti1, Diego Franciotta, Tiziana Vigo, Marina Grandis, Elisabetta Fiorina, Elisabetta Ghiglione, Luca Roccatagliata, Giovanni Luigi Mancardi, Antonio Uccelli, Angelo Schenone.   

Abstract

OBJECTIVE: To describe the unique case of a patient with multiple sclerosis (MS) and anti-myelin-associated glycoprotein (MAG) polyneuropathy who developed MS relapses after treatment with rituximab.
DESIGN: Case report.
SETTING: Department of Neurosciences, Ophthalmology, and Genetics, University of Genova, Genova, Italy. Patient A 59-year-old man with an 18-year history of MS presented with an unusually rapid progression of paraparesis with hypopallesthesia and areflexia in 4 limbs. Neurophysiological and serological studies led to the diagnosis of anti-MAG polyneuropathy. Cerebrospinal fluid analysis disclosed the loss of oligoclonal IgG bands that were previously detected at MS onset. Intervention Rituximab was administered at a dosage of 375 mg/m(2)/wk for 4 weeks. Result The patient developed 2 corticosteroid-responsive MS relapses with improvement of the polyneuropathy.
CONCLUSION: Rituximab can be effective in anti-MAG polyneuropathy but can possibly lead to unexpected consequences in individuals with MS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17923639     DOI: 10.1001/archneur.64.10.1531

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  15 in total

Review 1.  Potential importance of B cells in aging and aging-associated neurodegenerative diseases.

Authors:  Arya Biragyn; Maria Aliseychik; Evgeny Rogaev
Journal:  Semin Immunopathol       Date:  2017-01-12       Impact factor: 9.623

Review 2.  Update on therapy of chronic immune-mediated neuropathies.

Authors:  Chiara Briani; Dario Cocito; Marta Campagnolo; Pietro Emiliano Doneddu; Eduardo Nobile-Orazio
Journal:  Neurol Sci       Date:  2021-01-16       Impact factor: 3.307

3.  Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis.

Authors:  Takashi Matsushita; Mayuka Horikawa; Yohei Iwata; Thomas F Tedder
Journal:  J Immunol       Date:  2010-07-12       Impact factor: 5.422

4.  Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.

Authors:  Klaus Lehmann-Horn; Helena C Kronsbein; Martin S Weber
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

Review 5.  B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.

Authors:  Silke Kinzel; Martin S Weber
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

6.  A case of anti-myelin-associated glycoprotein polyneuropathy and multiple sclerosis: one disease instead of two?

Authors:  Stefano Sotgiu; Alessandra Giua; Maria R Murrighile; Renato Ortu
Journal:  BMJ Case Rep       Date:  2009-02-20

Review 7.  Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.

Authors:  Laurie S Davis; Andreas M Reimold
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

Review 8.  CD19: a promising B cell target for rheumatoid arthritis.

Authors:  Thomas F Tedder
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

9.  IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases.

Authors:  Ping Shen; Toralf Roch; Vicky Lampropoulou; Richard A O'Connor; Ulrik Stervbo; Ellen Hilgenberg; Stefanie Ries; Van Duc Dang; Yarúa Jaimes; Capucine Daridon; Rui Li; Luc Jouneau; Pierre Boudinot; Siska Wilantri; Imme Sakwa; Yusei Miyazaki; Melanie D Leech; Rhoanne C McPherson; Stefan Wirtz; Markus Neurath; Kai Hoehlig; Edgar Meinl; Andreas Grützkau; Joachim R Grün; Katharina Horn; Anja A Kühl; Thomas Dörner; Amit Bar-Or; Stefan H E Kaufmann; Stephen M Anderton; Simon Fillatreau
Journal:  Nature       Date:  2014-02-23       Impact factor: 49.962

Review 10.  Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.

Authors:  Henrik E Mei; Stefanie Schmidt; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2012-11-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.